These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19275456)

  • 1. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
    Nguyen TV; Filson J
    Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Komaba H; Tanaka M; Fukagawa M
    Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 5. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
    Uemura K; Kakuta T
    Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on the treatment of chronic kidney disease-mineral and bone disorder.
    Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
    J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
    Nakai K; Komaba H; Fukagawa M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
    Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
    Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm.
    Rastogi A; Bhatt N; Rossetti S; Beto J
    J Ren Nutr; 2021 Jan; 31(1):21-34. PubMed ID: 32386937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
    Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 19th Annual Meeting of the Japanese Society for Kidney Bone Disease.
    Akizawa T
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S1. PubMed ID: 19032519
    [No Abstract]   [Full Text] [Related]  

  • 20. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.